Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported ...

Metsera (NASDAQ:MTSR) added ~16% on Tuesday as Wall Street continued to cheer early-stage trial data the company posted for ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...

The newly listed clinical-stage biotechnology company, Metsera Inc. MTSR rose 15.01% on Monday as the broader markets declined. What Happened: While the company reported insider trades over the ...

Kristina Burow, a director at $MTSR, bought 1,432,224 shares of the company on 02-03-2025 for an estimated $25,780,032. This trade was reported by Quiver Quantitative ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...

Metsera (NASDAQ:MTSR) added ~16% on Tuesday as Wall Street continued to cheer early-stage trial data the company posted for its weight loss candidate MET-233i, which led MTSR shares to rally in ...